Tang Capital Management LLC's Increased Stake in Keros Therapeutics

Tang Capital Management LLC, along with related entities and Kevin Tang, has filed a Schedule 13G indicating an increased stake in Keros Therapeutics, Inc. As of October 15, 2025, the reporting entities beneficially own 2,418,984 shares of Keros Therapeutics' Common Stock, representing a 7.9% ownership. This marks a significant increase from previous holdings, with a value change of $18,333,107.44 and a shares change of 1,000,000. The filing highlights shared voting and dispositive power among the entities and Kevin Tang. The filing is made under Rule 13d-1(c) and includes a joint filing agreement among the entities.